Saturday, December 16, 2017 6:29:09 PM
— — — — — — — — — — — — — — — — —————
https://www.google.com/amp/s/www.yahoo.com/amphtml/finance/news/bravatek-executes-agreement-prominent-reseller-133000882.html
Bravatek and i3
Bravatek recently received a landmark commitment from Phil Oakley, CEO at iC3. Along with being named a cyber security software supplier for this $20B SEWP Contract, Phil Oakley has scheduled a meeting for Bravatek to present to the Cyber Chief of Technology of the US Army on July 19th in Washington, D.C. To help facilitate the communication process, Bravatek has developed an online digital communication center to help iC3 be able to share the features and benefits of our products and services to the dozens of Agency Chiefs and Department Heads that iC3 has been working with over the years. Now that we have the tools in place, Bravatek is looking to close deals with the majority of the Departments that have expressed an interest in increasing their cyber security.
Phil Oakley:
https://www.linkedin.com/in/phil-oakley-3912118
LINKING PHIL TO WHITE HOUSE
https://www.google.com/amp/s/mobile.nytimes.com/2017/06/18/us/politics/michael-flynn-intel-group-trump.amp.html
Mr. Flynn and Mr. Kian soon found a third partner: Philip Oakley, a former Army intelligence analyst, longtime Flynn friend, and owner of two small companies that provided software for defense and intelligence clients. They restarted Flynn Intel Group in June 2015, according to Delaware corporate records, pitching themselves as a premier private intelligence and cybersecurity advisory firm.
None of the partners responded to repeated attempts to contact them. But their business interests were closely intermingled. Beginning in 2015, Mr. Oakley’s firms employed Mr. Flynn as an adviser and paid him $90,000 in salary over 11 months.
BVTK's VP of Sales and CEO "on the road" today meeting with US Government and military organizations to close Ecrypt One business...
— Bravatek Solutions (@bravatek) July 19, 2017
ANY TIME BEFORE WE START SEEING DEAL AFTER DEAL AFTER DEAL
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM